SIT Pharma is pleased to announce the acquisition of MIZOLLEN® from THERABEL HEALTHCARE LIMITED.

MIZOLLEN® is a long-acting H1 antihistamine indicated for the symptomatic treatment of seasonal allergic rhino-conjunctivitis (hay fever), perennial allergic rhino- conjunctivitis and urticaria.

This acquisition represents a significant elevation for the French branch of SIT in France Market (DESMA Pharma), in terms of value and reputation inside the French Market.

Silvia Lunati, General manager of SIT Pharma, comments “The acquisition of MIZOLLEN® will permit to potentiate and integrate our portfolio and strengthen significantly our presence in France. It is a success that confirms SIT Pharma as a reliable partner for international acquisitions of mature branded medicines. SIT Pharma moreover confirm the objective to maintain the actual distribution network and so ensure MIZOLLEN® business continuity”.

About SIT Pharma  

SIT Pharma is a family-owned pharmaceutical company, based in Italy since 1927. Today is an international pharmaceutical group with with almost 100 years of experience and a history of prestigious acquisitions and global expansion. SIT Pharma is a reliable preferred acquirer for pharma businesses choosing to divest their “mature”, “established” or “tail” off-patent branded medicines.

In our manufacturing plants we assure to continue the high-quality manufacturing and the management of the medicines, aspiring to breathe new life into the medicines, investing great resources to renew the life cycle and give new stability and sustainability over the long-term.

SIT Pharma is present in five continents and in over seventy countries worldwide.